Published in Mol Med on November 27, 2007
Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes (2009) 1.23
β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res Treat (2011) 1.06
Contraction-induced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1. J Biol Chem (2012) 1.01
alpha1-Adrenergic receptor stimulates interleukin-6 expression and secretion through both mRNA stability and transcriptional regulation: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. Mol Pharmacol (2009) 0.94
β-blockers: a novel class of antitumor agents. Onco Targets Ther (2012) 0.84
Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol Genomics (2008) 0.84
Mice lacking the β2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia. ASN Neuro (2012) 0.80
Stress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cells. Braz J Med Biol Res (2014) 0.79
The inflammation-related gene S100A12 is positively regulated by C/EBPβ and AP-1 in pigs. Int J Mol Sci (2014) 0.75
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Signaling pathways for cardiac hypertrophy and failure. N Engl J Med (1999) 3.97
Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 3.76
IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol (2003) 3.26
Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A (1999) 3.13
Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest (1999) 2.94
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A (2001) 1.99
Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol (2002) 1.92
Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A (1989) 1.83
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation (2003) 1.81
Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation (2002) 1.65
Structure of the rat interleukin 6 gene and its expression in macrophage-derived cells. J Biol Chem (1989) 1.60
Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation (2005) 1.59
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation (2000) 1.37
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol (2007) 1.26
Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol (2001) 1.19
Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation (2000) 1.19
Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension (1999) 1.13
Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J Mol Cell Cardiol (2006) 1.12
Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res (2004) 1.07
Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res (2002) 0.99
Norepinephrine-induced interleukin-6 increase in rat hearts: differential signal transduction in myocytes and non-myocytes. Pflugers Arch (2003) 0.98
Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol Cell Biochem (2003) 0.91
Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem (2003) 0.90
Activation and inactivation of cAMP-response element-mediated gene transcription in cardiac myocytes. Cardiovasc Res (2001) 0.89
Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol (1998) 0.86
Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem Pharmacol (2001) 0.84
The role of innate immune responses in the heart in health and disease. Trends Cardiovasc Med (2004) 0.83
Preparation and culture of embryonic and neonatal heart muscle cells: modification of transport activity. Methods Enzymol (1989) 0.80
Quantitative aspects of stress-induced immunomodulation. Int Immunopharmacol (2001) 0.80
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem (2004) 5.00
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods (2005) 3.11
Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science (2010) 2.99
Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol (2003) 2.84
Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol (2003) 2.80
Widespread receptivity to neuropeptide PDF throughout the neuronal circadian clock network of Drosophila revealed by real-time cyclic AMP imaging. Neuron (2008) 2.73
Rehabilitation in Patients With Coronary Heart Disease: Participation and Its Effect on Prognosis. Dtsch Arztebl Int (2015) 2.69
Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res (2006) 2.66
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol (2009) 2.59
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58
Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci U S A (2003) 2.52
Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol (2008) 2.51
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature (2003) 2.38
Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med (2009) 2.16
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation (2002) 2.10
Phytophthora infestans effector AVR3a is essential for virulence and manipulates plant immunity by stabilizing host E3 ligase CMPG1. Proc Natl Acad Sci U S A (2010) 2.07
A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol (2011) 2.07
Dynamics of receptor/G protein coupling in living cells. EMBO J (2005) 2.06
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest (2014) 2.06
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med (2005) 2.02
Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med (2005) 1.99
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation (2011) 1.98
Fluorescent sensors for rapid monitoring of intracellular cGMP. Nat Methods (2006) 1.96
Intravascular embolization of venous catheter--causes, clinical signs, and management: a systematic review. JPEN J Parenter Enteral Nutr (2009) 1.94
NPP1, a Phytophthora-associated trigger of plant defense in parsley and Arabidopsis. Plant J (2002) 1.93
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med (2014) 1.89
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol (2013) 1.89
Phytotoxicity and innate immune responses induced by Nep1-like proteins. Plant Cell (2006) 1.88
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med (2007) 1.86
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med (2010) 1.84
Determination of onset of sexual maturation and mating behavior by melanocortin receptor 4 polymorphisms. Curr Biol (2010) 1.82
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A (2012) 1.82
Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol (2002) 1.81
Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. J Biol Chem (2005) 1.80
Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res (2002) 1.79
Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest (2004) 1.77
Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med (2004) 1.72
Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion. PLoS One (2009) 1.71
Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci (2010) 1.70
Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med (2008) 1.66
Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J (2012) 1.65
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A (2005) 1.63
Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol (2005) 1.60
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med (2008) 1.56
G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region. J Biol Chem (2005) 1.55
Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg (2005) 1.53
Gs activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem (2006) 1.52
Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem (2005) 1.50
FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells. Nat Protoc (2011) 1.45
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Transcoronary pacing in a porcine model--impact of guidewire insulation. J Invasive Cardiol (2011) 1.42
MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation (2013) 1.42
Disseminated intravascular coagulation: a matter for immune globulins in sepsis? Crit Care Med (2006) 1.41
Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol (2009) 1.39
Internalization determinants of the parathyroid hormone receptor differentially regulate beta-arrestin/receptor association. J Biol Chem (2001) 1.37
Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation (2004) 1.36
Septic cardiomyopathy - A not yet discovered cardiomyopathy? Exp Clin Cardiol (2006) 1.36
Cardiovascular disease, risk factors and heart rate variability in the elderly general population: design and objectives of the CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. BMC Cardiovasc Disord (2005) 1.33
Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol (2003) 1.33
Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J Biol Chem (2004) 1.30
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A (2006) 1.29
Communication of end-of-life decisions in European intensive care units. Intensive Care Med (2005) 1.28
Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat Protoc (2010) 1.28
Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med (2003) 1.25
Genetic regulation of serum phytosterol levels and risk of coronary artery disease. Circ Cardiovasc Genet (2010) 1.23
Cardiovascular diseases, risk factors and short-term heart rate variability in an elderly general population: the CARLA study 2002-2006. Eur J Epidemiol (2009) 1.22
Monitoring of cAMP synthesis and degradation in living cells. Physiology (Bethesda) (2006) 1.20
Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem (2010) 1.20
Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) (2006) 1.20
Different treatment options in chronic coronary artery disease: when is it the time for medical treatment, percutaneous coronary intervention or aortocoronary bypass surgery? Dtsch Arztebl Int (2009) 1.18
Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest (2007) 1.17
Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J (2012) 1.17
GPCR and G proteins: drug efficacy and activation in live cells. Mol Endocrinol (2009) 1.16
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med (2006) 1.15
Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2. J Biol Chem (2008) 1.14
Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem (2006) 1.14
Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2002) 1.14
A role for caspase-1 in heart failure. Circ Res (2007) 1.13